Please assess the completion status of the following clinical trial:

Trial Title: Lactic Acidosis During Entecavir(ETV)Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
1. for ETV or LAM group~   Inclusion criteria:~  * 18 and more than 18 years, and less than 65 years~  * HBV-related liver cirrhosis or acute-on-chronic liver failure~  * Prior documentation of chronic HBV infection at least 6 months before randomization~  * MELD score 18 and more than 18~  * Venous blood lactate level 2 and less than 2 mmol/L~   Exclusion criteria:~  * Age of 65 or older, or younger than 18~  * Patients with acute hepatitis B including acute liver failure~  * Acute-on-chronic liver failure precipitated by acute hepatitis A or acetaminophen intoxication~  * MELD score less than 18~  * entecavir, lamivudine, telbivudine, clevudine, adefovir or tenofovir treatment continued longer than 3 months before entry.~  * Evidence of genotypic or virological resistance to lamivudine, clevudine, telbivudine, or adefovir~  * Patients with elevated venous blood lactate levels more than 2 mmol/L~  * Recent episodes of active infection, hypotension (systolic blood pressure less than 90 mmHg), gastrointestinal or other active bleeding within 2 weeks before entry~  * Any alcohol intake within 2 weeks before entry~  * Recent use of acetaminophen, epinephrine, metformin, iron, isoniazid, propofol, salicylate, sulfasalazine, or valproic acid within 2 weeks before entry. Use of lactulose is permitted.~  * Presence of hepatocellular carcinoma. Patients with hepatocellular carcinoma meeting the Milan criteria can be permitted.~  * Any cancer other than hepatocellular carcinoma except cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis \& T1). Any cancer curatively treated at least 3 years prior to entry is permitted.~  * Patients with HIV infection~  * Female patients in pregnancy~2. for no NRTI group~Inclusion criteria:~* Age of 65 or older, or younger than 18~* Liver cirrhosis or acute-on-chronic liver failure not related with HBV~* MELD score 18 and more than 18~* Venous blood lactate level 2 and less than 2 mmol/L~Exclusion criteria:~* Age of 65 or older, or younger than 18~* Patients with positive HBsAg or IgM anti-HBc~* Acute-on-chronic liver failure precipitated by acute hepatitis A or acetaminophen intoxication~* MELD score less than 18~* Patients with elevated venous blood lactate levels more than 2 mmol/L~* Recent episodes of active infection, hypotension (systolic blood pressure less than 90 mmHg), gastrointestinal or other active bleeding within 2 weeks before entry~* Any alcohol intake within 2 weeks before entry~* Recent use of acetaminophen, epinephrine, metformin, iron, isoniazid, propofol, salicylate, sulfasalazine, or valproic acid within 2 weeks before entry. Use of lactulose is permitted.~* Presence of hepatocellular carcinoma. Patients with hepatocellular carcinoma within Milan criteria can be permitted.~* Any cancer other than hepatocellular carcinoma except cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis \& T1). Any cancer curatively treated at least 3 years prior to entry is permitted.~* Patients with HIV infection~* Female patients in pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- entecavir (Type: EXPERIMENTAL): Oral 0.5mg/day until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks.
- lamivudine (Type: ACTIVE_COMPARATOR): Oral 100mg/day lamivudine until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks.
- no NRTI group (Type: NO_INTERVENTION): hepatitis C virus associated LC patients for the calculation of lactic acidosis incidence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility